Could lenalidomide boost chemo for tough AML?
NCT ID NCT03118466
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether adding lenalidomide to standard MEC chemotherapy helps adults with relapsed or refractory acute myeloid leukemia (AML) achieve remission. 41 participants received the combination. The main goal was to see how many achieved complete remission. This study is completed, and results may show whether this approach is worth further testing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenalidomide plus mitoxantrone, etoposide, and cytarabine (MEC chemotherapy)
What this could lead to
If successful, this combination could improve remission rates in patients with hard-to-treat AML, offering a bridge to more definitive treatments like transplant.
What could go wrong
This is a small, early-phase study (41 participants) without a comparison group. Results may not apply broadly, and the added lenalidomide could increase side effects like low blood counts or infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02062, United States
-
Massachusetts general Hospital
Boston, Massachusetts, 02215, United States